SCHEMBL5863541

SCHEMBL5863541

c1cc(CNC2CCCCC2)ccn1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.67
KDM4E B2RXH2 3/20 0.60
PKM P14618 2/20 0.60
ALDH1A1 P00352 2/20 0.60
EPHX1 P07099 1/20 0.59
MAPT P10636 1/20 0.59
POLB P06746 1/20 0.58
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.54
HDAC1 Q13547 1/20 0.53
CXCL12 P48061 1/20 0.50
CXCR4 P61073 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
NAMPT P43490 1/20 0.47
CYP19A1 P11511 1/20 0.46
KDM1A O60341 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25992753 0.98 HRH3 (0.63) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL8812183 0.93 HRH3 (0.64) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL662613 0.90 KDM4E (0.59) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL10953965 0.86 HRH3 (0.88) HRH3KDM4EPKMALDH1A1POLB
SCHEMBL18920792 0.82 KDM1A (0.56) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL2657729 0.81 KDM4E (0.55) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL10995268 0.81 TAAR1 (0.59) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL28749536 0.81 KDM4E (0.55) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL24574127 0.80 HRH3 (0.71) HRH3KDM4EPKMALDH1A1EPHX1
SCHEMBL1847296 0.80 HRH3 (0.71) HRH3KDM4EPKMALDH1A1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820573-B1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2023-08-09 EP disclosed
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC HRH3 334/4885KDM4E 2536/4885PKM 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.